Search for content, post, videos

She is the new CEO of PainDrainer

anki-malmborg-hager

The e-health company has appointed Anki Malmborg Hager as their new CEO.

PainDrainer has since 2018 developed a web-based application for self-management of chronic pain improving the quality of life by giving individual prognosis on how to minimize the pain level through artificial intelligence. The company is now performing several clinical studies both in USA and Sweden, with a focus to demonstrate the value of its web-based application.

“PainDrainer is a very interesting start-up company that has developed an absolutely unique web-based application for self-management of chronic pain. Artificial intelligence and eHealth are two of the latest and most promising technologies that will rule much of our future, and I am excited to explore the potential of this type of business. I very much look forward to being part of this exciting company and build value in the coming years,” says Anki Malmborg Hager.

Long-standing experience

Anki Malmborg Hager has a long-standing experience of leading life science companies in their early start-up phases, with SenzaGen being the most recent achievement. At SenzaGen she was CEO for 5 years and took the company from a market cap of 5 to 500 million SEK. Prior to SenzaGen, Anki Malmborg Hager was acting CEO of Cantargia and Diaprost. She holds a doctorate degree in Immunotechnology from Lund University as well as a Pharma-MBA from Falconbury.

“I am very pleased to welcome Anki Malmborg Hager as CEO during this expansive growth phase of our innovation journey. She has solid commercial background in the life science sector and will add valuable expertise of developing this exciting and disruptive eHealth company. She also has exactly the necessary skills, vision and determination to build on the foundations that we laid so far,” says Carl Borrebaeck, acting CEO today.

Anki Malmborg Hager will start as CEO on September 1, focusing on the commercial development of PainDrainer, using its evidence based clinical data. Carl Borrebaeck will then take the role of Chairman of the Board.

Photo: Peter Hamlin


Read also

“Identify the potential of your idea”